Welcome to our dedicated page for Raphael Pharm news (Ticker: RAPH), a resource for investors and traders seeking the latest updates and insights on Raphael Pharm stock.
Raphael Pharm (RAPH) delivers innovative pharmaceutical solutions through advanced drug development and biotech research. This news hub provides investors and industry professionals with verified updates on the company's progress in addressing critical healthcare challenges.
Access a centralized repository of RAPH's official announcements, including clinical trial milestones, regulatory submissions, financial disclosures, and strategic partnerships. Our curated collection ensures you stay informed about therapeutic advancements and business developments shaping this biopharmaceutical innovator.
Discover updates spanning research breakthroughs, manufacturing expansions, and commercialization efforts. Content is organized for quick scanning while maintaining depth for analytical needs. Bookmark this page to monitor RAPH's evolving position in competitive therapeutic markets without relying on fragmented sources.
Raphael Pharmaceutical (OTCQB: RAPH) announced positive proof-of-concept clinical study results for its cannabinoid-based formula treating rheumatoid arthritis (RA). The study, conducted by Citruslabs under IRB approval, showed significant improvements in 12 adult participants over eight weeks.
Key findings include a 19.2% reduction in Disease Activity Score (DAS28), shifting patients from high to moderate disease activity. The percentage of participants in remission increased from 0% to 16.67%, while high disease activity cases decreased from 66.67% to 41.67%. Pain-related symptoms improved, with negative pain outcomes dropping from 75% to 50%, and morning stiffness decreased from 75% to 41.67%.
83.33% of participants expressed desire to continue treatment, and 91.67% would recommend it to others. The company aims to potentially partner with a global biopharma company for drug delivery format development and commercialization.
Raphael Pharmaceutical, a clinical-stage biotechnology company, is advancing a novel cannabinoid-based research platform. The company highlights its exclusive relationship with Rambam Health Care Campus, which provides cutting-edge facilities for cannabinoid research. Raphael's lead product candidate, HPC1, targets rheumatoid arthritis and has shown promise in preclinical studies. A clinical study for HPC1 began in May 2024, with results expected by the end of the year. The company also explores cannabinoid treatments for chronic lung inflammation and aims to commence FDA Phase I trials in 2025. Raphael's mission is to offer cost-effective, accessible treatments for inflammatory diseases.
